 NOVATO, Calif., April 27, 2021 GLOBE NEWSWIRE -- Ultragenyx Pharmaceutical Inc. NASDAQ: RARE, a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today announced that clinical, preclinical and manufacturing data from its investigational gene therapy programs will be presented at the American Society of Gene Cell Therapy ASGCT 24th Annual Meeting, which will be held virtually May 11-14, 2021. 